Skip to main content

Table 2 Glucose control, HbA1c, insulin delivered during baseline and study phase

From: Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI)

 

Baseline

MDI + CGM, 1 week

Study

AHCL, 12 weeks

P

HbA1c, (mmol/mol)

70 ± 18.6

48 ± 7.7

0.001

HbA1c, (%)

8.6 ± 1.7

6.5 ± 0.7

0.001

Sensor glucose (mg/dL)

198 ± 38

138 ± 12

0.001

Percent of sensor glucose values in range

  < 54 mg/dL

0.8 ± 0.7

0.5 ± 0.4

0.008

 54–70 mg/dL

2.4 ± 2.1

2.3 ± 1.2

0.624

 70–180 mg/dL

42.1 ± 18.7

78.8 ± 6.1

0.001

180–250 mg/dL

28.1 ± 9.7

13.4 ± 5.1

0.001

  > 250 mg/dL

26.6 ± 16.2

5.0 ± 2.2

0.001

 TDD, U/(kg/d)

0.9 ± 0.3

1.1 ± 0.3

0.008

 Basal insulin, as % of TDD

38.6 ± 7.5

31.6 ± 6.1

0.001

 Weight, kg

48.2 ± 18.5

49.3 ± 17.2

0.800

  1. All values are shown as mean ± SD
  2. MDI Multiple Daily Injections, SG Sensor glucose, TDD Total daily dose of insulin